Name (Synonyms) | Correlation | |
---|---|---|
drug2180 | Saline containing 1% Human serum albumin(solution without UC-MSCs) Wiki | 1.00 |
drug2580 | UC-MSCs Wiki | 0.45 |
Name (Synonyms) | Correlation | |
---|---|---|
D014777 | Virus Diseases NIH | 0.12 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Maraviroc, a C-C Chemokine Receptor 5 (CCR5) antagonist, is well-tolerated without significant side effects in its current use in patients with HIV. CCR5 antagonism prior to the 'second wave' of inflammatory mediator expression in SARS-CoV-2 may reverse lymphoid depletion and may alter cell trafficking of inflammatory cells, both increasing viral control capacity and dampening damage to lung tissue, respectively. This study seeks to establish whether one week of treatment with Maraviroc, used at its approved dosage for HIV, is safe and tolerable in patients with SARS-CoV-2.
Description: Rate of subjects who complete the 7-day course of Maraviroc without discontinuation for serious adverse event or death.
Measure: Rate of Completion Time: 7 daysDescription: Percent of patients at Day 7 from enrollment achieving reduction of two points on a seven-category ordinal scale (defined below). Ordinal scale: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities OR hospitalized pending disposition, not requiring COVID-related care; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring ECMO, invasive mechanical ventilation, or both; and, 7, death.
Measure: Clinical improvement at Day 7 Time: 7 daysDescription: Measurement of Chi3l1 before, during and at completion of therapy.
Measure: Change in Chitinase 3-like 1(Chi3l1) (ng/mL) Time: 7 daysDescription: Measurement of IL-6 before, during and at completion of therapy.
Measure: Change in Interleukin-6 (IL-6) (pg/mL) Time: 7 DaysDescription: Measurement of CCL5 before, during and at completion of therapy.
Measure: Change in CCL5 (RANTES) (ng/mL) Time: 7 DaysDescription: 7-, 14- and 28-day all-cause-mortality
Measure: Mortality Time: 28 daysDescription: Time to improvement to Score of 2 or less (Days)
Measure: Time to Discharge Time: 28 days